NCT06862700 Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
| NCT ID | NCT06862700 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiaotong Hou |
| Condition | Cardiogenic Shock |
| Study Type | OBSERVATIONAL |
| Enrollment | 534 participants |
| Start Date | 2025-02-26 |
| Primary Completion | 2027-01-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support. * First-time ECMO initiation. * Venoarterial ECMO (VA-ECMO) as the initial mode. Exclusion Criteria: * Age \<18 years. * Severe pulmonary hypertension. * Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia). * Severe missing data.